Catalog No.
DHC12001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
IGF-I, IGF1, Mechano growth factor, MGF, Insulin-like growth factor I, IBP1, Somatomedin-C, IGF2, IGF-II, Insulin-like growth factor II, T3M-11-derived growth factor, Somatomedin-A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05019 & P01344
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BI 836845, CAS: 1417158-65-6
Clone ID
Xentuzumab
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer, PMID: 33451345
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models, PMID: 32054790
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer, PMID: 29367764
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models, PMID: 27614046
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing Antibody, PMID: 31562819
Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage, PMID: 29735545
Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin, PMID: 24296829
Quantification of binding of IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 mice, PMID: 24424057
Radioresistant laryngeal cancers upregulate type 1 IGF receptor and exhibit increased cellular dependence on IGF and EGF signalling, PMID: 31536667
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours, PMID: 32161368
For research use only. Not for human or drug use.
